< 1 minute read
Aug. 15, 2021

LNP023: A selective factor B serine protease inhibitor

LNP023

selective factor B serine protease inhibitor orally available, retinal barrier penetrant J. Med. Chem., Feb. 19, 2020 Novartis (NIBR), Cambridge, MA

twitterlinkedinprintemail